| 000 | 01633 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250511211213.0 | ||
| 264 | 0 | _c19910924 | |
| 008 | 199109s 0 0 eng d | ||
| 022 | _a0167-6997 | ||
| 024 | 7 |
_a10.1007/BF00175086 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCrown, J P | |
| 245 | 0 | 0 |
_aMitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. _h[electronic resource] |
| 260 |
_bInvestigational new drugs _cMay 1991 |
||
| 300 |
_a185-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 |
_aHodgkin Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitoguazone _xadministration & dosage |
| 650 | 0 | 4 |
_aMitoxantrone _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aRemission Induction _xmethods |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 700 | 1 | _aGulati, S | |
| 700 | 1 | _aStraus, D J | |
| 700 | 1 | _aKolitz, J | |
| 700 | 1 | _aHeelan, R | |
| 700 | 1 | _aO'Brien, J | |
| 700 | 1 | _aLee, B J | |
| 700 | 1 | _aPortlock, C | |
| 700 | 1 | _aBertino, J | |
| 773 | 0 |
_tInvestigational new drugs _gvol. 9 _gno. 2 _gp. 185-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF00175086 _zAvailable from publisher's website |
| 999 |
_c1880804 _d1880804 |
||